DETAILED ACTION
This office action is in response to the Applicant’s filing dated May 4th, 2026.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
This application is a 371 of PCT/CN2021/098707 filed on June 7th, 2021; and claims benefit of foreign priority of CN2021105834508 filed on May 27th, 2021. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55.
Status of Claims
Claims 1-20 are pending in the instant application. Acknowledgement is made of Applicant’s
remarks and amendments filed on May 4th, 2026. Acknowledgment is made of Applicant’s amendment of claims 1, 7, 9, 14 and 17.
Applicants elected without traverse Group I; as well as the species Compound IA-3 in the reply filed on January 8th, 2026. Claims 8, 10, 15-16 and 18-20 remain withdrawn.
In view of the claim amendments filed on May 4th, 2026, examination has been expanded to encompass the compound shown below:
PNG
media_image1.png
290
514
media_image1.png
Greyscale
which is a compound of instantly claimed Formula (X2) wherein Z is absent; wherein X is O; wherein Y is NH; wherein R2 is an unsubstituted C6-12 aryl, specifically phenyl; and wherein R3 is a halogen, specifically F.
A prior art search was conducted for the expanded to compound.
This search retrieved prior art.
Therefore, the Examiner’s search will not be extended unnecessarily to additional species in/for/during this Office action.
Claims 1-7, 9, 11-14 and 17 read on the elected species and will be examined herein.
Objections and/or Rejections and Response to Arguments
Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated (Maintained Objections and/or Rejections) or newly applied (New Objections and/or Rejections, Necessitated by Amendment or New Objections and/or Rejections, NOT Necessitated by Amendment). They constitute the complete set presently being applied to the instant application.
New Objections and/or Rejections
Necessitated by Claim Amendment
Claim Objections
Claims 4-7, 13-14 and 17 are objected to in part as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims, and to recite only the elected species Compound IA-3.
Note that claims 4-7, 13-14 and 17 are objected to “in part” herein insofar as it contains non-elected subject matter to which the prior art search has not yet been extended. That part which has been searched, however (consistent with the election of species requirement as previously discussed), would be allowable if the claim was amended in independent form including all the limitations of the base claim and any intervening claims, and to remove the currently non-elected subject matter.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-3, 9 and 11-12 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Tantak et al (Bioorganic & Medicinal Chemistry Letters, (2015), 25(19), 4225-4231).
Regarding claims 1-3, 9 and 11-12, Tantak teaches Compound 17f shown below (page 4227, Table 1):
PNG
media_image1.png
290
514
media_image1.png
Greyscale
which is a compound of instantly claimed Formula (X2) wherein Z is absent; wherein X is O; wherein Y is NH; wherein R2 is an unsubstituted C6-12 aryl, specifically phenyl; and wherein R3 is a halogen, specifically F. This is the compound expanded to by the Examiner. Tantak further discloses Compound 17f in solution with a solvent, 0.05-0.1% DMSO (page 4228, right column, fifth paragraph); which reads on a pharmaceutical excipient (carrier).
Thus, the teachings of Tantak anticipate the compound and composition of instant claims 1-3, 9, and 11-12.
Conclusion
Claims 1-3, 9 and 11-12 are rejected.
Claims 4-7, 13-14 and 17 are objected to.
No claim is allowed.
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER L JOHNSON whose telephone number is (571)272-1672. The examiner can normally be reached Monday - Friday 08:00AM - 5:00PM EST with Flex on Fridays.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/C.L.J./Examiner, Art Unit 1691
/RENEE CLAYTOR/Supervisory Patent Examiner, Art Unit 1691
Prosecution Insights